Advertisement

Document › Details
Cobra Biologics Ltd.. (1/23/18). "Press Release: Cobra Biologics Awarded £2.6m ($3.4m USD) from Innovate UK". Keele.
![]() |
Region | United Kingdom (GB) |
![]() |
Organisation | Cobra Biologics Ltd. |
Group | Cobra Biologics (Group) | |
Organisation 2 | United Kingdom (GB) (govt) | |
![]() |
Product | contract manufacturing (biologicals) |
Product 2 | business development (state/region) | |
![]() |
Person | Coleman, Peter (Cobra Biologics 201106 CEO– before RecipharmCobra Biologics) |
Person 2 | Fairhead, Rona (United Kingdom (govt) 201801 Minister of State for Trade and Exports) | |
> Capital infrastructure investment to embed and secure clinical and commercial viral vector manufacturing capability within the UK
> Award made as part of UK’s Innovation Agency’s Industrial Strategy boost for UK medicines with £70m of funding to help develop new treatments
Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, announced that it has been awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK. The award has been made under Innovate UK’s Industrial Strategy boost for UK medicines with £70 million of funding to help develop new treatments. The investment will go towards a £5 million development project, which forms part of a wider £15 million company expansion announced by Cobra in 2017, to advance world leading capabilities for clinical and commercial production of viral vectors and DNA, vital for gene therapy and immune-oncology programmes.
The extended capacity and capability will allow Cobra increased process development, analytics and GMP manufacturing, and importantly provides the necessary infrastructure to offer commercial in-market supply of viral vector and DNA products to Advanced Therapy Medicinal Product (ATMP) developers. The expansion will double the footprint of Cobra’s UK site and create 25-35 additional jobs.
Peter Coleman, Chief Executive of Cobra Biologics, commented: “Cobra is undertaking a very significant expansion of our viral and DNA manufacturing capability and we are very pleased to have received funding from Innovate UK to help accelerate our plans. The investment recognises Cobra as a leading company in the cell and gene therapy market and provides us, and the UK, with a unique opportunity to be at the forefront of developing revolutionary disease therapies and new treatments for patients.”
Minister of State for Trade and Exports, Baroness Rona Fairhead said: “The UK is a world leader in the Life Sciences industry, and our advanced gene therapies offer the potential to improve dramatically the lives of millions.
“The expansion of Cobra is an exciting development. It will create further highly skilled jobs and allow Cobra to drive their exports, while demonstrating UK leadership in another industry of the future.”
ENDS
Notes to Editors:
Peter Coleman, CEO Cobra Biologics
For a high resolution images please contact sarah.jeffery@zymecommunications.com
Contacts
Media enquiries
Sarah Jeffery
Zyme Communications
E-mail: sarah.jeffery@zymecommunications.com
Phone: +44 (0)7771 730919
At Cobra Biologics
Peter Coleman
Chief Executive Officer
E-mail: peter.coleman@cobrabio.com
Phone: +44 (0)1782 714181
About Cobra Biologics
Cobra Biologics is a leading international contract development and manufacturing organisation (CDMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.
Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.
As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.
For more information please visit: www.cobrabio.com
About Innovate UK
Innovate UK is the UK's innovation agency. It drives productivity and growth by supporting businesses to realise the potential of new technologies, develop ideas and make them a commercial success.
With a strong business focus, Innovate UK drives growth by working with companies to de-risk, enable and support innovation.
For further information visit: www.innovateuk.org
https://www.gov.uk/government/news/improved-healthcare-for-all-pioneering-projects-get-funding
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/672702/Viral_Vector_Manufacturing_for_Cell_and_Gene_Therapies_-_Challenge_Fund_-_Competition_Results.pdf
https://www.gov.uk/government/news/industrial-strategy-boost-for-uk-medicines-with-70-million-of-funding-to-help-develop-new-treatments
Record changed: 2018-02-01 |
Advertisement

More documents for Cobra Biologics (Group)
- [1] Cobra Biologics Ltd.. (11/26/18). "Press Release: Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies". Keele & Port Washington, NY & London....
- [2] Cobra Biologics Ltd.. (10/30/18). "Press Release: Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project". Keele & Leeds....
- [3] Cobra Biologics Ltd.. (4/18/17). "Press Release: Cobra Biologics Embarks On £15m (165m SEK) Gene Therapy Manufacturing Operations Expansion". Keele & Matfors & Södertälje....
- [4] Cobra Biologics Ltd.. (6/23/16). "Press Release: Cobra Biologics and Alligator Bioscience Extend Drug Development Partnership". Södertälje & Lund....
- [5] Cobra Biologics Ltd.. (6/7/16). "Press Release: Cobra Biologics and Touchlight Collaborate on Production of Next Generation DNA Constructs". Keele & London....
- [6] Cobra Biologics Ltd.. (4/13/16). "Press Release: Cobra and Lancaster Partnership Helps Unravel New Analytical Tool for DNA Topology"....
- [7] Cobra Biologics Ltd.. (2/25/16). "Press Release: Cobra Biologics and Centre for Process Innovation Announce Collaboration to Advance Development of Regenerative Medicines". Keele & Cleveland....
- [8] Cobra Biologics Ltd.. (9/24/15). "Press Release: Cobra Biologics and the University of Manchester Announce Collaboration to Improve Industrial Scale-up". Keele & Manchester....
- [9] Vaccibody AS. (6/21/13). "Press Release: Vaccibody Raised 733.000 €"....
- [10] Algeta ASA. (8/16/12). "Press Release: Algeta Initiates New R&D Program to Investigate a Targeted Thorium Conjugate (TTC) against Hematological Cancer [Not intended for US media]". Oslo....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top